{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:08:47Z","timestamp":1789985327855,"version":"4.0.1"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1097\/med.0000000000000096","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T13:04:27Z","timestamp":1407416667000},"page":"422-429","source":"Crossref","is-referenced-by-count":28,"title":["Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis"],"prefix":"10.1097","volume":"21","author":[{"given":"Oranan","family":"Siwamogsatham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin","family":"Tangpricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20211004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis.","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"key":"R3-17-20211004","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.2337\/dc10-1279","article-title":"Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"R4-17-20211004","first-page":"1267","article-title":"Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis.","volume":"81","author":"Couce","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-17-20211004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0046-8177(84)80191-4","article-title":"Endocrine pancreas in cystic fibrosis: an immunohistochemical study.","volume":"15","author":"Iannucci","year":"1984","journal-title":"Hum Pathol"},{"key":"R6-17-20211004","first-page":"153","article-title":"Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.","volume":"30","author":"Ntimbane","year":"2009","journal-title":"Clin Biochem Rev"},{"key":"R7-17-20211004","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-3476(95)70080-3","article-title":"Genetic determination of diabetes mellitus in patients with cystic fibrosis. Multicenter Cystic Fibrosis Study Group.","volume":"127","author":"Rosenecker","year":"1995","journal-title":"J Pediatr"},{"key":"R8-17-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1099-0496(200101)31:1<1::AID-PPUL1000>3.0.CO;2-T","article-title":"European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations.","volume":"31","author":"Koch","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"R9-17-20211004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/jaut.2001.0532","article-title":"Autoantibodies to pancreatic hsp60 precede the development of glucose intolerance in patients with cystic fibrosis.","volume":"17","author":"Jensen","year":"2001","journal-title":"J Autoimmun"},{"key":"R10-17-20211004","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcf.2005.09.011","article-title":"Calpain 10 and development of diabetes mellitus in cystic fibrosis.","volume":"5","author":"Derbel","year":"2006","journal-title":"J Cyst Fibros"},{"key":"R11-17-20211004","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1007\/s00125-009-1436-2","article-title":"A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis.","volume":"52","author":"Blackman","year":"2009","journal-title":"Diabetologia"},{"key":"R12-17-20211004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/acta.0.1280207","article-title":"Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance.","volume":"128","author":"Lanng","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"R13-17-20211004","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0022-3476(05)80032-0","article-title":"Pancreatic endocrine function in cystic fibrosis.","volume":"118","author":"Moran","year":"1991","journal-title":"J Pediatr"},{"key":"R14-17-20211004","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcf.2013.06.001","article-title":"Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test.","volume":"13","author":"Schmid","year":"2014","journal-title":"J Cyst Fibros"},{"key":"R15-17-20211004","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/diab.43.8.1020","article-title":"Insulin sensitivity in cystic fibrosis.","volume":"43","author":"Moran","year":"1994","journal-title":"Diabetes"},{"key":"R16-17-20211004","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.metabol.2004.06.015","article-title":"Insulin regulation of free fatty acid kinetics in adult cystic fibrosis patients with impaired glucose tolerance.","volume":"53","author":"Moran","year":"2004","journal-title":"Metabolism"},{"key":"R17-17-20211004","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2337\/diabetes.50.6.1336","article-title":"Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance.","volume":"50","author":"Moran","year":"2001","journal-title":"Diabetes"},{"key":"R18-17-20211004","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1399-5448.2009.00632.x","article-title":"Oral glucose tolerance testing in children with cystic fibrosis.","volume":"11","author":"Ode","year":"2010","journal-title":"Pediatr Diabetes"},{"key":"R19-17-20211004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0022-3476(98)70171-4","article-title":"Abnormal glucose metabolism in cystic fibrosis.","volume":"133","author":"Moran","year":"1998","journal-title":"J Pediatr"},{"key":"R20-17-20211004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0168-8227(99)00058-3","article-title":"Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report.","volume":"45","author":"Moran","year":"1999","journal-title":"Diabetes Res Clin Pract"},{"key":"R21-17-20211004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000271912","article-title":"Cystic fibrosis-related diabetes in childhood.","volume":"73","author":"ORiordan","year":"2010","journal-title":"Horm Res Paediatr"},{"key":"R22-17-20211004","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ppul.1142","article-title":"Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis.","volume":"32","author":"Koch","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"R23-17-20211004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","article-title":"Epidemiology of cystic fibrosis-related diabetes.","volume":"146","author":"Marshall","year":"2005","journal-title":"J Pediatr"},{"key":"R24-17-20211004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0022-3476(88)80315-9","article-title":"Diabetes mellitus associated with cystic fibrosis.","volume":"112","author":"Finkelstein","year":"1988","journal-title":"J Pediatr"},{"key":"R25-17-20211004","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","article-title":"Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline.","volume":"162","author":"Milla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"R26-17-20211004","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/080352501750197647","article-title":"Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus.","volume":"90","author":"Nousia-Arvanitakis","year":"2001","journal-title":"Acta Paediatr"},{"key":"R27-17-20211004","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2337\/diacare.23.1.126b","article-title":"HbA1c is not recommended as a screening test for diabetes in cystic fibrosis.","volume":"23","author":"Holl","year":"2000","journal-title":"Diabetes Care"},{"key":"R28-17-20211004","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"R29-17-20211004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcf.2005.09.001","article-title":"Relationship between glycosylated haemoglobin and mean plasma glucose concentration in cystic fibrosis.","volume":"5","author":"Brennan","year":"2006","journal-title":"J Cyst Fibros"},{"key":"R30-17-20211004","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc10-2289","article-title":"Hyperglycemia and death in cystic fibrosis-related diabetes.","volume":"34","author":"Adler","year":"2011","journal-title":"Diabetes Care"},{"issue":"Suppl 12","key":"R32-17-20211004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1399-5448.2009.00587.x","article-title":"Management of cystic fibrosis-related diabetes in children and adolescents.","volume":"10","author":"ORiordan","year":"2009","journal-title":"Pediatr Diabetes"},{"key":"R33-17-20211004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2013.02.008","article-title":"Update on cystic fibrosis-related diabetes.","volume":"12","author":"Kelly","year":"2013","journal-title":"J Cyst Fibros"},{"key":"R34-17-20211004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MED.0b013e32833a780d","article-title":"Recent trends in cystic fibrosis-related diabetes.","volume":"17","author":"Nathan","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R35-17-20211004","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jpeds.2009.10.019","article-title":"Natural history of glucose intolerance in patients with cystic fibrosis: ten-year prospective observation program.","volume":"156","author":"Sterescu","year":"2010","journal-title":"J Pediatr"},{"key":"R36-17-20211004","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1590\/S0004-27302011000800016","article-title":"Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD).","volume":"55","author":"Noronha","year":"2011","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"R37-17-20211004","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2337\/diacare.24.10.1706","article-title":"Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes.","volume":"24","author":"Moran","year":"2001","journal-title":"Diabetes Care"},{"key":"R38-17-20211004","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6823-6-4","article-title":"Insulin versus oral agents in the management of cystic fibrosis related diabetes: a case based study.","volume":"6","author":"Onady","year":"2006","journal-title":"BMC Endocr Disord"},{"key":"R39-17-20211004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.nu.13.070193.000551","article-title":"Nutritional management of cystic fibrosis.","volume":"13","author":"Pencharz","year":"1993","journal-title":"Annu Rev Nutr"},{"key":"R40-17-20211004","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review.","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"R41-17-20211004","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1463-1326.2010.01250.x","article-title":"Managing diabetes in cystic fibrosis.","volume":"12","author":"Laguna","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"R42-17-20211004","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2337\/dc06-1576","article-title":"Microvascular complications in cystic fibrosis-related diabetes.","volume":"30","author":"Schwarzenberg","year":"2007","journal-title":"Diabetes Care"},{"key":"R43-17-20211004","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.2337\/dc06-0654","article-title":"Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications.","volume":"29","author":"Andersen","year":"2006","journal-title":"Diabetes Care"},{"key":"R44-17-20211004","first-page":"445","article-title":"Bone disease in cystic fibrosis: whats new Joint Bone S","volume":"78","author":"Javier","year":"2011","journal-title":"pine"},{"key":"R46-17-20211004","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1183\/09031936.04.00050204","article-title":"Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor.","volume":"25","author":"King","year":"2005","journal-title":"Eur Respir J"},{"key":"R47-17-20211004","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/thx.2006.075887","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone.","volume":"62","author":"Shead","year":"2007","journal-title":"Thorax"},{"key":"R48-17-20211004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcf.2009.11.005","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone.","volume":"9","author":"Le Heron","year":"2010","journal-title":"J Cyst Fibros"},{"key":"R49-17-20211004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2265.2012.04484.x","article-title":"The impact of dysglycaemia on bone mineral accrual in young people with cystic fibrosis.","volume":"78","author":"Rana","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R50-17-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","article-title":"The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis.","volume":"86","author":"Paccou","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"R51-17-20211004","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.mcp.0000142923.00683.d2","article-title":"Treatment of bone disease in cystic fibrosis.","volume":"10","author":"Aris","year":"2004","journal-title":"Curr Opin Pulm Med"},{"issue":"Suppl 2","key":"R52-17-20211004","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","article-title":"European cystic fibrosis bone mineralisation guidelines.","volume":"10","author":"Sermet-Gaudelus","year":"2011","journal-title":"J Cyst Fibros"},{"key":"R53-17-20211004","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2265.2008.03216.x","article-title":"Vitamin D and bone health in adults with cystic fibrosis.","volume":"69","author":"Wolfenden","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R54-17-20211004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/MCP.0b013e3283659e35","article-title":"Cystic fibrosis-related bone disease.","volume":"19","author":"Paccou","year":"2013","journal-title":"Curr Opin Pulm Med"},{"key":"R55-17-20211004","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jcf.2008.02.001","article-title":"Exercise during childhood and adolescence: a prophylaxis against cystic fibrosis-related low bone mineral density Exercise for bone health in children with cystic fibrosis.","volume":"7","author":"Hind","year":"2008","journal-title":"J Cyst Fibros"},{"key":"R57-17-20211004","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008482.pub3","article-title":"Vitamin K supplementation for cystic fibrosis.","volume":"4","author":"Jagannath","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R58-17-20211004","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00003495-200464020-00002","article-title":"Management of osteoporosis in adults with cystic fibrosis.","volume":"64","author":"Hecker","year":"2004","journal-title":"Drugs"},{"key":"R59-17-20211004","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/thx.2002.002568","article-title":"Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study.","volume":"59","author":"Conway","year":"2004","journal-title":"Thorax"},{"key":"R60-17-20211004","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1164\/ajrccm.162.3.2002051","article-title":"Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.","volume":"162","author":"Aris","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"R61-17-20211004","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/thorax.56.4.314","article-title":"Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis.","volume":"56","author":"Haworth","year":"2001","journal-title":"Thorax"},{"key":"R62-17-20211004","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jcf.2011.07.007","article-title":"Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis.","volume":"10","author":"Haworth","year":"2011","journal-title":"J Cyst Fibros"},{"key":"R63-17-20211004","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(05)79826-3","article-title":"Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis.","volume":"352","author":"Haworth","year":"1998","journal-title":"Lancet"},{"key":"R64-17-20211004","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"R66-17-20211004","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis.","volume":"357","author":"Canalis","year":"2007","journal-title":"N Engl J Med"},{"key":"R67-17-20211004","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide recombinant human parathyroid hormone (1-34) with alendronate in postmenopausal women with osteoporosis.","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R68-17-20211004","doi-asserted-by":"crossref","first-page":"CR442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.","volume":"17","author":"Panico","year":"2011","journal-title":"Med Sci Monit"},{"key":"R71-17-20211004","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bpg.2005.11.006","article-title":"Cystic fibrosis: nutritional consequences and management.","volume":"20","author":"Dodge","year":"2006","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R72-17-20211004","first-page":"280","article-title":"Vitamin D bioavailability in cystic fibrosis: a cause for concern Nutr R","volume":"70","author":"Mailhot","year":"2012","journal-title":"ev"},{"key":"R73-17-20211004","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1210\/jc.2008-2012","article-title":"Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light.","volume":"94","author":"Khazai","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R74-17-20211004","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/archdischild-2011-301398","article-title":"Vitamin D in children with cystic fibrosis.","volume":"97","author":"Brodlie","year":"2012","journal-title":"Arch Dis Child"},{"key":"R75-17-20211004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/0884533614530170","article-title":"Relationship between fat-soluble vitamin supplementation and blood concentrations in adolescent and adult patients with cystic fibrosis.","volume":"29","author":"Siwamogsatham","year":"2014","journal-title":"Nutr Clin Pract"},{"key":"R76-17-20211004","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1210\/jc.2011-3050","article-title":"An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation.","volume":"97","author":"Tangpricha","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R77-17-20211004","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1515\/jpem-2012-0012","article-title":"Growth failure in children with cystic fibrosis.","volume":"25","author":"Scaparrotta","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R78-17-20211004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/eje.0.1400315","article-title":"Normal spontaneous and stimulated GH levels despite decreased IGF-I concentrations in cystic fibrosis patients.","volume":"140","author":"Laursen","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"R79-17-20211004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jcf.2012.08.003","article-title":"Growth retardation and reduced growth hormone secretion in cystic fibrosis. clinical observations from three CF centers.","volume":"12","author":"Ciro","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"R80-17-20211004","first-page":"731","article-title":"Growth problems and growth hormone treatment in children with cystic fibrosis.","volume":"15","author":"Hardin","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R81-17-20211004","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0899-9007(98)00086-0","article-title":"Nutrition and cystic fibrosis.","volume":"14","author":"Wilson","year":"1998","journal-title":"Nutrition"},{"key":"R82-17-20211004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1569-1993(02)00032-2","article-title":"Nutrition in patients with cystic fibrosis: a European Consensus.","volume":"1","author":"Sinaasappel","year":"2002","journal-title":"J Cyst Fibros"},{"key":"R83-17-20211004","doi-asserted-by":"crossref","first-page":"e1211","DOI":"10.1542\/peds.2010-2007","article-title":"Recombinant human growth hormone in the treatment of patients with cystic fibrosis.","volume":"126","author":"Phung","year":"2010","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"R84-17-20211004","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1530\/eje.0.151s081","article-title":"GH improves growth and clinical status in children with cystic fibrosis -- a review of published studies.","volume":"151","author":"Hardin","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"R85-17-20211004","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1210\/jc.2006-1101","article-title":"Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial.","volume":"91","author":"Hardin","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R86-17-20211004","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jpeds.2004.10.037","article-title":"Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition.","volume":"146","author":"Hardin","year":"2005","journal-title":"J Pediatr"},{"key":"R87-17-20211004","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/archpedi.1984.02140420054017","article-title":"Short stature and pubertal delay in male adolescents with cystic fibrosis. Androgen treatment.","volume":"138","author":"Landon","year":"1984","journal-title":"Am J Dis Child"},{"key":"R88-17-20211004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.99.1.29","article-title":"Delayed puberty in girls with cystic fibrosis despite good clinical status.","volume":"99","author":"Johannesson","year":"1997","journal-title":"Pediatrics"},{"key":"R89-17-20211004","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1651-2227.2003.tb02571.x","article-title":"Pubertal growth and development in cystic fibrosis: a retrospective review.","volume":"92","author":"Aswani","year":"2003","journal-title":"Acta Paediatr"},{"key":"R90-17-20211004","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jpeds.2013.02.026","article-title":"Pubertal height velocity and associations with prepubertal and adult heights in cystic fibrosis.","volume":"163","author":"Zhang","year":"2013","journal-title":"J Pediatr"},{"key":"R91-17-20211004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0197-0070(83)80367-2","article-title":"Menstrual dysfunction in cystic fibrosis.","volume":"4","author":"Neinstein","year":"1983","journal-title":"J Adolesc Healthcare"},{"key":"R92-17-20211004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2478\/v10042-010-0051-x","article-title":"Age of menarche in girls with cystic fibrosis.","volume":"48","author":"Umlawska","year":"2010","journal-title":"Folia Histochem Cytobiol"},{"key":"R93-17-20211004","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/GCO.0b013e32835f1745","article-title":"Cystic fibrosis and fertility.","volume":"25","author":"Ahmad","year":"2013","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R94-17-20211004","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S0140-6736(94)90292-5","article-title":"Congenital bilateral absence of vas deferens in the absence of cystic fibrosis.","volume":"344","author":"Augarten","year":"1994","journal-title":"Lancet"},{"key":"R95-17-20211004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1530\/eje.0.1480551","article-title":"Sex steroids and body composition in men with cystic fibrosis.","volume":"148","author":"Leifke","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"R96-17-20211004","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0022-3476(71)80324-4","article-title":"Complications of iodide therapy in patients with cystic fibrosis.","volume":"79","author":"Dolan","year":"1971","journal-title":"J Pediatr"},{"key":"R97-17-20211004","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0022-3476(81)80638-5","article-title":"Thyroid gland function and pituitary TSH reserve in patients with cystic fibrosis.","volume":"98","author":"Segall-Blank","year":"1981","journal-title":"J Pediatr"},{"key":"R98-17-20211004","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF00442510","article-title":"Thyroid function in children with cystic fibrosis.","volume":"138","author":"De Luca","year":"1982","journal-title":"Eur J Pediatr"},{"key":"R99-17-20211004","first-page":"111","article-title":"Abnormal thyroid function and response to iodides in patients with cystic fibrosis.","volume":"87","author":"Azizi","year":"1974","journal-title":"Trans Assoc Am Physicians"},{"key":"R100-17-20211004","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jtemb.2012.08.002","article-title":"Iodine deficiency and subclinical hypothyroidism are common in cystic fibrosis patients.","volume":"27","author":"Naehrlich","year":"2013","journal-title":"J Trace Elem Med Biol"},{"key":"R101-17-20211004","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0022-3476(05)80250-1","article-title":"Altered prednisolone pharmacokinetics in patients with cystic fibrosis.","volume":"120","author":"Dove","year":"1992","journal-title":"J Pediatr"},{"key":"R102-17-20211004","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1569-1993(03)00022-5","article-title":"Inhaled budesonide induced Cushings syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450.","volume":"2","author":"De Wachter","year":"2003","journal-title":"J Cyst Fibros"},{"key":"R103-17-20211004","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1651-2227.2002.tb02894.x","article-title":"Cushings syndrome due to pharmacological interaction in a cystic fibrosis patient.","volume":"91","author":"Main","year":"2002","journal-title":"Acta Paediatr"},{"key":"R104-17-20211004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2012.10.007","article-title":"Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression in adults with cystic fibrosis.","volume":"12","author":"Gilchrist","year":"2013","journal-title":"J Cyst Fibros"},{"key":"R105-17-20211004","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/thorax.57.8.749","article-title":"Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis.","volume":"57","author":"Parmar","year":"2002","journal-title":"Thorax"}],"container-title":["Current Opinion in Endocrinology, Diabetes &amp; Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01266029-201410000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T13:13:16Z","timestamp":1633525996000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01266029-201410000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0000000000000096","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}